Journal article · 2022 · Open access
Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
Clinical Pharmacology & Therapeutics, 113(1), 135–151 · Published 4 November 2022 · DOI 10.1002/cpt.2766
In brief
“Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making” is a 2022 journal article by Elisabeth Bakker and 5 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 98 citations as of 22 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 98
- Most cited in
- 2025 (28)
- Field-weighted impact
- 11.39
- References
- 17
- Authors
- 6
Abstract
Real-world data/evidence (RWD/RWE) may provide insightful information on medicines' clinical effects to guide regulatory decisions. While its contribution has been recognized for safety monitoring and disease epidemiology across medicines' life cycles, using RWD/RWE to demonstrate efficacy requires further evaluation. This study aimed to (i) characterize RWD/RWE presented by applicants to support claims on medicines' efficacy within initial marketing authorization applications (MAAs) and extension of indication applications (EoIs), and (ii) analyze the contribution of RWD/RWE to regulatory decisions on medicines' benefit-risk profile. RWD/RWE was included to support efficacy in 32 MAAs and 14 EoIs submitted 2018-2019. Of these, RWD/RWE was part of the preauthorization package of 16 MAAs and 10 EoIs, and was (i) considered supporting the regulatory decision in 10 applications (five MAAs, five EoIs), (ii) considered not supporting the regulatory decision in 11 (seven MAAs, four EoIs), and (iii) not addressed at all in the evaluation of 5 applications (four MAAs, one EoI). Common limitations of submitted RWD/RWE included missing data, lack of representativeness of populations, small sample size, absence of an adequate or prespecified analysis plan, and risk of several types of bias. The suitability of RWD/RWE in a given application still requires a case-by-case analysis considering its purpose of use, implying reflection on the data source, together with its assets and limitations, study objectives and designs, and the overall data package issued. Early interactions and continuous dialogues with regulators and relevant stakeholders is key to optimize fit-for-purpose RWE generation, enabling its broader use in medicines development.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Bakker, E., Plueschke, K., Jonker, C. J., Kurz, X., Starokozhko, V., & Mol, P. G. M. (2022). Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making. Clinical Pharmacology & Therapeutics, 113(1), 135–151. https://doi.org/10.1002/cpt.2766
MLA 9
Bakker, Elisabeth, et al. “Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making.” Clinical Pharmacology & Therapeutics, vol. 113, no. 1, 2022, pp. 135–151. https://doi.org/10.1002/cpt.2766.
Chicago
Bakker, Elisabeth, Kelly Plueschke, Carla J. Jonker, Xavier Kurz, Viktoriia Starokozhko, and Peter G. M. Mol. 2022. “Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making.” Clinical Pharmacology & Therapeutics 113 (1): 135–151. https://doi.org/10.1002/cpt.2766.
Harvard
Bakker, E. et al. (2022) ‘Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making’, Clinical Pharmacology & Therapeutics, 113(1), pp. 135–151. doi:10.1002/cpt.2766.
IEEE
E. Bakker, K. Plueschke, C. J. Jonker, X. Kurz, V. Starokozhko, and P. G. M. Mol, “Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making,” Clinical Pharmacology & Therapeutics, vol. 113, no. 1, pp. 135–151, 2022, doi: 10.1002/cpt.2766.
BibTeX
@article{bakker2022contribution,
title = {{Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making}},
author = {Bakker, Elisabeth and Plueschke, Kelly and Jonker, Carla J. and Kurz, Xavier and Starokozhko, Viktoriia and Mol, Peter G. M.},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2022},
volume = {113},
number = {1},
pages = {135--151},
doi = {10.1002/cpt.2766},
url = {https://doi.org/10.1002/cpt.2766}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 19 | |
| 2024 | 26 | |
| 2025 | 28 | |
| 2026 | 24 |
Its field-weighted citation impact is 11.39: it has been cited 11.39 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- real-world evidence
- real-world data
- regulatory decision-making
- European Medicines Agency
- marketing authorization applications
- efficacy claims
- risk-benefit assessment
- regulatory interactions
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Bakker, E., Plueschke, K., Jonker, C. J., Kurz, X., Starokozhko, V., & Mol, P. G. M. (2022). Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making. Clinical Pharmacology & Therapeutics, 113(1), 135–151. https://doi.org/10.1002/cpt.2766
How many times has this paper been cited?
98 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Elisabeth Bakker, Kelly Plueschke, Carla J. Jonker, Xavier Kurz, Viktoriia Starokozhko, Peter G. M. Mol.
What is the DOI of this paper?
10.1002/cpt.2766, permanently at https://doi.org/10.1002/cpt.2766. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.